NC
NCYT.LSE Novacyt
- Market cap
- GBX 25.5M
- P/E
- -
- P/B
- 1.41x
- ROE
- -92.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NCYT.LSE undervalued?
Graham numberThe Graham number of Novacyt cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novacyt fundamental analysis
No fundamental analysis for Novacyt yet.
Novacyt stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, a…
Full company profileNovacyt financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novacyt annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.1M | 12.8M | 12.4M | 11.5M | 277M | 92.6M | 21.0M | 11.6M | 19.6M | 20.4M | 34.5M |
| Gross Profit | 5.91M | 7.14M | 7.76M | 7.34M | 211M | 63.5M | 5.75M | 3.73M | 32.1M | 7.88M | 17.0M |
| Operating Income | -3.80M | -123K | -1.25M | -1.56M | 167M | 36.0M | -23.4M | -29.5M | -37.3M | -13.2M | -15.0M |
| EBITDA | -2.29M | 1.00M | 39.3K | 473K | 175M | 43.9M | -15.5M | -18.2M | -8.80M | -8.21M | -11.5M |
| Net Income | -4.87M | -4.83M | -4.27M | -6.28M | 132M | -9.73M | -25.7M | -28.3M | -41.8M | -23.3M | -17.3M |
| EPS | -0.40 | -0.21 | -0.11 | -0.14 | 1.94 | -0.14 | -0.36 | -0.40 | -0.59 | -0.33 | -0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 30.4M | 30.2M | 29.3M | 30.0M | 234M | 184M | 141M | 134M | 70.6M | 40.3M | 37.7M |
| Total Liabilities | 12.7M | 9.17M | 11.2M | 14.1M | 83.6M | 41.9M | 25.7M | 46.6M | 22.8M | 16.9M | 19.0M |
| Shareholders' Equity | 17.8M | 22.1M | 20.1M | 14.1M | 151M | 142M | 115M | 87.2M | 47.9M | 23.3M | 18.7M |
| Cash & Short-term Investments | 2.87M | 4.38M | 1.03M | 1.55M | 91.8M | 102M | 87.0M | 44.1M | 30.5M | 19.1M | 8.93M |
| Total Debt | 5.33M | 3.46M | 5.28M | 10.6M | 2.38M | 1.87M | 872K | 13.7M | 11.9M | 10.4M | 10.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.18M | -4.12M | -1.12M | -917K | 103M | 15.7M | -13.7M | -25.0M | -9.82M | -8.75M | -13.3M |
| Capital Expenditure | 467K | 868K | 617K | 287K | 1.18M | 4.10M | 416K | 671K | 1.86M | 273K | 367K |
| Free Cash Flow | -2.65M | -4.99M | -1.74M | -1.20M | 102M | 11.6M | -14.1M | -25.7M | -11.0M | -9.03M | -13.7M |
| Ratios | |||||||||||
| ROE | -27.4% | -21.8% | -21.2% | -44.6% | 87.9% | -6.9% | -22.3% | -32.4% | -87.2% | -99.9% | -92.3% |
| ROA | -16.0% | -16.0% | -14.6% | -20.9% | 56.5% | -5.3% | -18.3% | -21.1% | -59.1% | -57.9% | -45.9% |
| Net Profit Margin | -44.0% | -37.6% | -34.5% | -54.8% | 47.8% | -10.5% | -122.3% | -244.3% | -212.7% | -114.2% | -50.1% |
| Debt to Equity | 0.30x | 0.16x | 0.26x | 0.75x | 0.02x | 0.01x | 0.01x | 0.16x | 0.25x | 0.45x | 0.55x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novacyt dividends
Novacyt has not paid dividends in the last 9 fiscal years.
Who owns Novacyt
- Insiders 0.06%
- Institutions 0.00%
- Public & others 99.94%
- Shares outstanding 72.5M
- Free float 71.6M
Novacyt company profile
- Company name
- Novacyt
- Ticker
- NCYT.LSE
- ISIN
- FR0010397232
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 228
- Fiscal year end
- December
- Address
- 131 Boulevard Carnot, Le Vésinet, France, 78110
- Phone
- 33 1 39 46 51 04
- Website
- novacyt.com
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.
Novacyt management
4- Mr. Lyn Dafydd ReesCEO & Executive Director · born 1973
- Mr. Steve GibsonCFO, Company Secretary & Director
- Mr. Peter CoyneChief Operations Officer
- Ms. Wendy CoxDirector of HR